Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 125 entries
Sorted by: Best Match Show Resources per page
Rapid identification of extensively and extremely drug resistant tuberculosis from multidrug resistant strains; using PCR-RFLP and PCR-SSCP.

Iranian journal of microbiology

Tahmasebi P, Farnia P, Sheikholslami F, Velayati A.
PMID: 23205246
Iran J Microbiol. 2012 Dec;4(4):165-70.

BACKGROUND AND OBJECTIVES: Resistance in Mycobacterium tuberculosis is caused by mutations in genes encoding drug targets. Investigators have already demonstrated the existence of mutations in codons 88 to 94 in the gyrA gene and also in codons 1400, 1401,...

Cite
Tahmasebi P, Farnia P, Sheikholslami F, et al. Rapid identification of extensively and extremely drug resistant tuberculosis from multidrug resistant strains; using PCR-RFLP and PCR-SSCP. Iran J Microbiol. 2012;4(4):165-70
Tahmasebi, P., Farnia, P., Sheikholslami, F., & Velayati, A. (2012). Rapid identification of extensively and extremely drug resistant tuberculosis from multidrug resistant strains; using PCR-RFLP and PCR-SSCP. Iranian journal of microbiology, 4(4), 165-70.
Tahmasebi, P, et al. "Rapid identification of extensively and extremely drug resistant tuberculosis from multidrug resistant strains; using PCR-RFLP and PCR-SSCP." Iranian journal of microbiology vol. 4,4 (2012): 165-70.
Tahmasebi P, Farnia P, Sheikholslami F, Velayati A. Rapid identification of extensively and extremely drug resistant tuberculosis from multidrug resistant strains; using PCR-RFLP and PCR-SSCP. Iran J Microbiol. 2012 Dec;4(4):165-70. PMID: 23205246; PMCID: PMC3507304.
Copy Download .nbib Format: NLM
Effects of stevia on glycemic and lipid profile of type 2 diabetic patients: A randomized controlled trial.

Avicenna journal of phytomedicine

Ajami M, Seyfi M, Abdollah Pouri Hosseini F, Naseri P, Velayati A, Mahmoudnia F, Zahedirad M, Hajifaraji M.
PMID: 32257884
Avicenna J Phytomed. 2020 Mar-Apr;10(2):118-127.

OBJECTIVE: Stevia (MATERIALS AND METHODS: A double-blind clinical trial was carried out in 34 type 2 diabetic patients. These patients were assigned into two groups of stevia (n=15) (received 1 cup of 2% stevia extract-sweet tea in three meals)...

Cite
Ajami M, Seyfi M, Abdollah Pouri Hosseini F, et al. Effects of stevia on glycemic and lipid profile of type 2 diabetic patients: A randomized controlled trial. Avicenna J Phytomed. 2020;10(2):118-127
Ajami, M., Seyfi, M., Abdollah Pouri Hosseini, F., Naseri, P., Velayati, A., Mahmoudnia, F., Zahedirad, M., & Hajifaraji, M. (2020). Effects of stevia on glycemic and lipid profile of type 2 diabetic patients: A randomized controlled trial. Avicenna journal of phytomedicine, 10(2), 118-127.
Ajami, Marjan, et al. "Effects of stevia on glycemic and lipid profile of type 2 diabetic patients: A randomized controlled trial." Avicenna journal of phytomedicine vol. 10,2 (2020): 118-127.
Ajami M, Seyfi M, Abdollah Pouri Hosseini F, Naseri P, Velayati A, Mahmoudnia F, Zahedirad M, Hajifaraji M. Effects of stevia on glycemic and lipid profile of type 2 diabetic patients: A randomized controlled trial. Avicenna J Phytomed. 2020 Mar-Apr;10(2):118-127. PMID: 32257884; PMCID: PMC7103435.
Copy Download .nbib Format: NLM
Safety and Efficacy of Hepatic Artery Embolization in Treating Solitary Fibrous Tumor Metastatic to the Liver.

Sarcoma

Velayati S, Erinjeri JP, Brody LA, Ziv E, Boas FE, Brown KT, Covey AM, Getrajdman GI, Solomon SB, Kingham PT, Tap WD, Jarnagin WR, Yarmohammadi H.
PMID: 31565028
Sarcoma. 2019 Sep 03;2019:3060658. doi: 10.1155/2019/3060658. eCollection 2019.

The aim of this study was to evaluate safety and survival following hepatic artery embolization (HAE) for metastatic solitary fibrous tumor (SFT) in the liver. All patients with SFT metastatic to liver treated with HAE were retrospectively analyzed. Tumor...

Cite
Velayati S, Erinjeri JP, Brody LA, et al. Safety and Efficacy of Hepatic Artery Embolization in Treating Solitary Fibrous Tumor Metastatic to the Liver. Sarcoma. 2019;2019:3060658doi: 10.1155/2019/3060658.
Velayati, S., Erinjeri, J. P., Brody, L. A., Ziv, E., Boas, F. E., Brown, K. T., Covey, A. M., Getrajdman, G. I., Solomon, S. B., Kingham, P. T., Tap, W. D., Jarnagin, W. R., & Yarmohammadi, H. (2019). Safety and Efficacy of Hepatic Artery Embolization in Treating Solitary Fibrous Tumor Metastatic to the Liver. Sarcoma, 20193060658. https://doi.org/10.1155/2019/3060658
Velayati, Sara, et al. "Safety and Efficacy of Hepatic Artery Embolization in Treating Solitary Fibrous Tumor Metastatic to the Liver." Sarcoma vol. 2019 (2019): 3060658. doi: https://doi.org/10.1155/2019/3060658
Velayati S, Erinjeri JP, Brody LA, Ziv E, Boas FE, Brown KT, Covey AM, Getrajdman GI, Solomon SB, Kingham PT, Tap WD, Jarnagin WR, Yarmohammadi H. Safety and Efficacy of Hepatic Artery Embolization in Treating Solitary Fibrous Tumor Metastatic to the Liver. Sarcoma. 2019 Sep 03;2019:3060658. doi: 10.1155/2019/3060658. eCollection 2019. PMID: 31565028; PMCID: PMC6745165.
Copy Download .nbib Format: NLM
Biochemical Basis of Cyfluthrin and DDT Resistance in .

Journal of arthropod-borne diseases

Gorouhi MA, Oshaghi MA, Vatandoost H, Enayati AA, Raeisi A, Abai MR, Salim-Abadie Y, Hanafi-Bojd AA, Paksa A, Nikpoor F.
PMID: 30584554
J Arthropod Borne Dis. 2018 Sep 30;12(3):310-320. eCollection 2018 Sep.

METHODS: Field mosquito specimens were collected from Chabahar Seaport, southeast corner of Iran, in 2015. Insecticide susceptibility and enzyme assays were conducted as recommended by WHO.RESULTS: Mean enzyme ratios were 3.95 and 3.04 for α- esterases and 2.40 and...

Cite
Gorouhi MA, Oshaghi MA, Vatandoost H, et al. Biochemical Basis of Cyfluthrin and DDT Resistance in . J Arthropod Borne Dis. 2018;12(3):310-320
Gorouhi, M. A., Oshaghi, M. A., Vatandoost, H., Enayati, A. A., Raeisi, A., Abai, M. R., Salim-Abadie, Y., Hanafi-Bojd, A. A., Paksa, A., & Nikpoor, F. (2018). Biochemical Basis of Cyfluthrin and DDT Resistance in . Journal of arthropod-borne diseases, 12(3), 310-320.
Gorouhi, Mohammad Amin, et al. "Biochemical Basis of Cyfluthrin and DDT Resistance in ." Journal of arthropod-borne diseases vol. 12,3 (2018): 310-320.
Gorouhi MA, Oshaghi MA, Vatandoost H, Enayati AA, Raeisi A, Abai MR, Salim-Abadie Y, Hanafi-Bojd AA, Paksa A, Nikpoor F. Biochemical Basis of Cyfluthrin and DDT Resistance in . J Arthropod Borne Dis. 2018 Sep 30;12(3):310-320. eCollection 2018 Sep. PMID: 30584554; PMCID: PMC6297723.
Copy Download .nbib Format: NLM
Pulmonary complications of predominantly antibody immunodeficiencies in a tertiary lung center.

Interventional medicine & applied science

Mahdaviani SA, Darougar S, Mansouri D, Tashayoie-Nejad S, Movahedi M, Aghdam KR, Ghaffaripour H, Baghaie N, Hassanzad M, Eslaminejad A, Fakharian A, Pourdowlat G, Heshmatnia J, Bakhshayeshkaram M, Boloursaz M, Tabarsi P, Hashemitari SK, Velayati AA.
PMID: 32148897
Interv Med Appl Sci. 2019 Mar;11(1):1-7. doi: 10.1556/1646.10.2018.49.

BACKGROUND AND AIMS: Respiratory infections are expressed very soon in the life in humoral immunodeficiencies and often lead to chronic irreversible complications such as bronchiectasis and chronic airflow limitation. This study was conducted to evaluate the pulmonary complications of...

Cite
Mahdaviani SA, Darougar S, Mansouri D, et al. Pulmonary complications of predominantly antibody immunodeficiencies in a tertiary lung center. Interv Med Appl Sci. 2019;11(1):1-7doi: 10.1556/1646.10.2018.49.
Mahdaviani, S. A., Darougar, S., Mansouri, D., Tashayoie-Nejad, S., Movahedi, M., Aghdam, K. R., Ghaffaripour, H., Baghaie, N., Hassanzad, M., Eslaminejad, A., Fakharian, A., Pourdowlat, G., Heshmatnia, J., Bakhshayeshkaram, M., Boloursaz, M., Tabarsi, P., Hashemitari, S. K., & Velayati, A. A. (2019). Pulmonary complications of predominantly antibody immunodeficiencies in a tertiary lung center. Interventional medicine & applied science, 11(1), 1-7. https://doi.org/10.1556/1646.10.2018.49
Mahdaviani, Seyed Alireza, et al. "Pulmonary complications of predominantly antibody immunodeficiencies in a tertiary lung center." Interventional medicine & applied science vol. 11,1 (2019): 1-7. doi: https://doi.org/10.1556/1646.10.2018.49
Mahdaviani SA, Darougar S, Mansouri D, Tashayoie-Nejad S, Movahedi M, Aghdam KR, Ghaffaripour H, Baghaie N, Hassanzad M, Eslaminejad A, Fakharian A, Pourdowlat G, Heshmatnia J, Bakhshayeshkaram M, Boloursaz M, Tabarsi P, Hashemitari SK, Velayati AA. Pulmonary complications of predominantly antibody immunodeficiencies in a tertiary lung center. Interv Med Appl Sci. 2019 Mar;11(1):1-7. doi: 10.1556/1646.10.2018.49. PMID: 32148897; PMCID: PMC7044568.
Copy Download .nbib Format: NLM
Association of specific viral infections with childhood asthma exacerbations.

Interventional medicine & applied science

Hassanzad M, Nadji SA, Darougar S, Tashayoie-Nejad S, Boloursaz MR, Mahdaviani SA, Baghaie N, Ghaffaripour H, Velayati AA.
PMID: 32148899
Interv Med Appl Sci. 2019 Mar;11(1):17-20. doi: 10.1556/1646.10.2018.35.

INTRODUCTION: Asthma exacerbations may occur due to a variety of triggers including respiratory viruses. The aim of this study was to determine the role of particular viral infections in asthma exacerbations in children.MATERIALS AND METHODS: The study was performed...

Cite
Hassanzad M, Nadji SA, Darougar S, et al. Association of specific viral infections with childhood asthma exacerbations. Interv Med Appl Sci. 2019;11(1):17-20doi: 10.1556/1646.10.2018.35.
Hassanzad, M., Nadji, S. A., Darougar, S., Tashayoie-Nejad, S., Boloursaz, M. R., Mahdaviani, S. A., Baghaie, N., Ghaffaripour, H., & Velayati, A. A. (2019). Association of specific viral infections with childhood asthma exacerbations. Interventional medicine & applied science, 11(1), 17-20. https://doi.org/10.1556/1646.10.2018.35
Hassanzad, Maryam, et al. "Association of specific viral infections with childhood asthma exacerbations." Interventional medicine & applied science vol. 11,1 (2019): 17-20. doi: https://doi.org/10.1556/1646.10.2018.35
Hassanzad M, Nadji SA, Darougar S, Tashayoie-Nejad S, Boloursaz MR, Mahdaviani SA, Baghaie N, Ghaffaripour H, Velayati AA. Association of specific viral infections with childhood asthma exacerbations. Interv Med Appl Sci. 2019 Mar;11(1):17-20. doi: 10.1556/1646.10.2018.35. PMID: 32148899; PMCID: PMC7044566.
Copy Download .nbib Format: NLM
Leukocytoclastic vasculitis in patients with IL12B or IL12RB1 deficiency: case report and review of the literature.

Pediatric rheumatology online journal

Sharifinejad N, Mahdaviani SA, Jamee M, Daneshmandi Z, Moniri A, Marjani M, Tabarsi P, Farnia P, Rekabi M, Fallahi M, Hashemimoghaddam SA, Mohkam M, Bustamante J, Casanova JL, Mansouri D, Velayati AA.
PMID: 34389021
Pediatr Rheumatol Online J. 2021 Aug 13;19(1):121. doi: 10.1186/s12969-021-00623-0.

BACKGROUND: Mendelian susceptibility to mycobacterial disease (MSMD) is an inborn error of immunity, resulting in susceptibility to weakly virulent mycobacteria and other intramacrophagic pathogens. Rheumatologic manifestations and vasculitis are considered rare manifestations in MSMD patients.CASE PRESENTATION: In this study,...

Cite
Sharifinejad N, Mahdaviani SA, Jamee M, et al. Leukocytoclastic vasculitis in patients with IL12B or IL12RB1 deficiency: case report and review of the literature. Pediatr Rheumatol Online J. 2021;19(1):121doi: 10.1186/s12969-021-00623-0.
Sharifinejad, N., Mahdaviani, S. A., Jamee, M., Daneshmandi, Z., Moniri, A., Marjani, M., Tabarsi, P., Farnia, P., Rekabi, M., Fallahi, M., Hashemimoghaddam, S. A., Mohkam, M., Bustamante, J., Casanova, J. L., Mansouri, D., & Velayati, A. A. (2021). Leukocytoclastic vasculitis in patients with IL12B or IL12RB1 deficiency: case report and review of the literature. Pediatric rheumatology online journal, 19(1), 121. https://doi.org/10.1186/s12969-021-00623-0
Sharifinejad, Niusha, et al. "Leukocytoclastic vasculitis in patients with IL12B or IL12RB1 deficiency: case report and review of the literature." Pediatric rheumatology online journal vol. 19,1 (2021): 121. doi: https://doi.org/10.1186/s12969-021-00623-0
Sharifinejad N, Mahdaviani SA, Jamee M, Daneshmandi Z, Moniri A, Marjani M, Tabarsi P, Farnia P, Rekabi M, Fallahi M, Hashemimoghaddam SA, Mohkam M, Bustamante J, Casanova JL, Mansouri D, Velayati AA. Leukocytoclastic vasculitis in patients with IL12B or IL12RB1 deficiency: case report and review of the literature. Pediatr Rheumatol Online J. 2021 Aug 13;19(1):121. doi: 10.1186/s12969-021-00623-0. PMID: 34389021; PMCID: PMC8361607.
Copy Download .nbib Format: NLM
Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.

International immunopharmacology

Hashemian SM, Khoundabi B, Velayati AA.
PMID: 34217670
Int Immunopharmacol. 2021 May 28;107693. doi: 10.1016/j.intimp.2021.107693. Epub 2021 May 28.

No abstract available.

Cite
Hashemian SM, Khoundabi B, Velayati AA. Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. Int Immunopharmacol. 2021;107693doi: 10.1016/j.intimp.2021.107693.
Hashemian, S. M., Khoundabi, B., & Velayati, A. A. (2021). Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. International immunopharmacology, 107693. https://doi.org/10.1016/j.intimp.2021.107693
Hashemian, Seyed MohammadReza, et al. "Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia." International immunopharmacology vol. (2021): 107693. doi: https://doi.org/10.1016/j.intimp.2021.107693
Hashemian SM, Khoundabi B, Velayati AA. Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. Int Immunopharmacol. 2021 May 28;107693. doi: 10.1016/j.intimp.2021.107693. Epub 2021 May 28. PMID: 34217670; PMCID: PMC8162908.
Copy Download .nbib Format: NLM
First Report of Target Site Insensitivity in Pyrethroid Resistant .

Journal of arthropod-borne diseases

Ahmed-Yusuf M, Vatandoost H, Oshaghi MA, Hanafi-Bojd AA, Enayati AA, Jalo RI.
PMID: 33644236
J Arthropod Borne Dis. 2020 Sep 30;14(3):228-238. doi: 10.18502/jad.v14i3.4556. eCollection 2020 Sep.

BACKGROUND: Malaria is a major public health problem and life threatening parasitic vector-borne disease. For the first time, we established and report the molecular mechanism responsible for METHODS: The susceptibility profile of RESULTS: The mosquitoes were all resistant to...

Cite
Ahmed-Yusuf M, Vatandoost H, Oshaghi MA, et al. First Report of Target Site Insensitivity in Pyrethroid Resistant . J Arthropod Borne Dis. 2020;14(3):228-238doi: 10.18502/jad.v14i3.4556.
Ahmed-Yusuf, M., Vatandoost, H., Oshaghi, M. A., Hanafi-Bojd, A. A., Enayati, A. A., & Jalo, R. I. (2020). First Report of Target Site Insensitivity in Pyrethroid Resistant . Journal of arthropod-borne diseases, 14(3), 228-238. https://doi.org/10.18502/jad.v14i3.4556
Ahmed-Yusuf, Mustapha, et al. "First Report of Target Site Insensitivity in Pyrethroid Resistant ." Journal of arthropod-borne diseases vol. 14,3 (2020): 228-238. doi: https://doi.org/10.18502/jad.v14i3.4556
Ahmed-Yusuf M, Vatandoost H, Oshaghi MA, Hanafi-Bojd AA, Enayati AA, Jalo RI. First Report of Target Site Insensitivity in Pyrethroid Resistant . J Arthropod Borne Dis. 2020 Sep 30;14(3):228-238. doi: 10.18502/jad.v14i3.4556. eCollection 2020 Sep. PMID: 33644236; PMCID: PMC7903364.
Copy Download .nbib Format: NLM
Does symbiotic supplementation which contains .

Archives of physiology and biochemistry

Velayati A, Kareem I, Sedaghat M, Sohrab G, Nikpayam O, Hedayati M, Abhari K, Hejazi E.
PMID: 34077686
Arch Physiol Biochem. 2021 Jun 02;1-8. doi: 10.1080/13813455.2021.1928225. Epub 2021 Jun 02.

This study aimed to determine the effect of

Cite
Velayati A, Kareem I, Sedaghat M, et al. Does symbiotic supplementation which contains . Arch Physiol Biochem. 2021;1-8doi: 10.1080/13813455.2021.1928225.
Velayati, A., Kareem, I., Sedaghat, M., Sohrab, G., Nikpayam, O., Hedayati, M., Abhari, K., & Hejazi, E. (2021). Does symbiotic supplementation which contains . Archives of physiology and biochemistry, 1-8. https://doi.org/10.1080/13813455.2021.1928225
Velayati, Aynaz, et al. "Does symbiotic supplementation which contains ." Archives of physiology and biochemistry vol. (2021): 1-8. doi: https://doi.org/10.1080/13813455.2021.1928225
Velayati A, Kareem I, Sedaghat M, Sohrab G, Nikpayam O, Hedayati M, Abhari K, Hejazi E. Does symbiotic supplementation which contains . Arch Physiol Biochem. 2021 Jun 02;1-8. doi: 10.1080/13813455.2021.1928225. Epub 2021 Jun 02. PMID: 34077686.
Copy Download .nbib Format: NLM
Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial.

Gastroenterology and hepatology from bed to bench

Marjani M, Fahim F, Sadr M, Kazempour Dizaji M, Moniri A, Khabiri S, Tabarsi P, Velayati AA.
PMID: 31191838
Gastroenterol Hepatol Bed Bench. 2019;12(2):138-142.

AIM: This study was performed to evaluate the potential efficacy of silymarin in the management of anti-tuberculosis medication's induced liver injury.BACKGROUND: Hepatic toxicity is the most serious complication in treatment of tuberculosis.METHODS: In a randomized double blind clinical trial...

Cite
Marjani M, Fahim F, Sadr M, et al. Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial. Gastroenterol Hepatol Bed Bench. 2019;12(2):138-142
Marjani, M., Fahim, F., Sadr, M., Kazempour Dizaji, M., Moniri, A., Khabiri, S., Tabarsi, P., & Velayati, A. A. (2019). Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial. Gastroenterology and hepatology from bed to bench, 12(2), 138-142.
Marjani, Majid, et al. "Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial." Gastroenterology and hepatology from bed to bench vol. 12,2 (2019): 138-142.
Marjani M, Fahim F, Sadr M, Kazempour Dizaji M, Moniri A, Khabiri S, Tabarsi P, Velayati AA. Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial. Gastroenterol Hepatol Bed Bench. 2019;12(2):138-142. PMID: 31191838; PMCID: PMC6536020.
Copy Download .nbib Format: NLM
Update on Immunology of COVID-19 Disease and Potential Strategy for Controlling.

Tanaffos

Dezfuli NK, Adcock IM, Montazami N, Mortaz E, Velayati A.
PMID: 33959165
Tanaffos. 2020 Dec;19(4):274-290.

Coronavirus disease 2019 (COVID-19) is caused by a novel form of the coronavirus that caused severe acute respiratory syndrome (SARS). SARS-CoV-2 raised in China and has broadcast to 261 countries globally. SARS-CoV-2 a member of β-coronavirus family and has...

Cite
Dezfuli NK, Adcock IM, Montazami N, et al. Update on Immunology of COVID-19 Disease and Potential Strategy for Controlling. Tanaffos. 2020;19(4):274-290
Dezfuli, N. K., Adcock, I. M., Montazami, N., Mortaz, E., & Velayati, A. (2020). Update on Immunology of COVID-19 Disease and Potential Strategy for Controlling. Tanaffos, 19(4), 274-290.
Dezfuli, Neda K, et al. "Update on Immunology of COVID-19 Disease and Potential Strategy for Controlling." Tanaffos vol. 19,4 (2020): 274-290.
Dezfuli NK, Adcock IM, Montazami N, Mortaz E, Velayati A. Update on Immunology of COVID-19 Disease and Potential Strategy for Controlling. Tanaffos. 2020 Dec;19(4):274-290. PMID: 33959165; PMCID: PMC8088154.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 125 entries